A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2018
At a glance
- Drugs Alpelisib (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Status changed from completed to discontinued.
- 30 Jun 2016 Status changed from active, no longer recruiting to completed.